Radioiodine therapy for castration-resistant prostate cancer following prostate-specific membrane antigen promoter-mediated transfer of the human sodium iodide symporter

Asian Journal of Andrology

Volumn 16, Issue 1, 2014, Pages 120-123

  Gao, Xiao Feng ^a   Zhou, Tie ^a   Chen, Guang Hua ^a   Xu, Chuan Liang ^a   Ding, Ye Lei ^a   Sun, Ying Hao ^a  

^a SECOND MILITARY MEDICAL UNIVERSITY   (China)

Author keywords

genetic therapy; prostate specific membrane antigen (PSMA); prostatic neoplasms; sodium iodide symporter

Indexed keywords

ADENOVIRUS VECTOR; ANDROGEN; IODINE 131; PROSTATE SPECIFIC MEMBRANE ANTIGEN; SODIUM IODIDE SYMPORTER;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER CELL CULTURE; CANCER GENE THERAPY; CANCER RADIOTHERAPY; CASTRATION RESISTANT PROSTATE CANCER; CELL STRAIN LNCAP; CELL STRUCTURE; CONTROLLED STUDY; DRUG EFFICACY; DRUG UPTAKE; GENE EXPRESSION; GENE TRANSFER; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MALE; MOUSE; NONHUMAN; PROMOTER REGION; PROSTATE ADENOCARCINOMA; RADIOISOTOPE THERAPY; TREATMENT RESPONSE; TUMOR VOLUME; TUMOR XENOGRAFT; VIRAL GENE DELIVERY SYSTEM;

ADENOVIRIDAE; ANIMALS; ANTIGENS, SURFACE; CELL LINE, TUMOR; GENETIC THERAPY; GLUTAMATE CARBOXYPEPTIDASE II; IODINE RADIOISOTOPES; MALE; MICE; PROSTATIC NEOPLASMS, CASTRATION-RESISTANT; SYMPORTERS; TRANSFECTION;

EID: 84891959986     PISSN: 1008682X     EISSN: 17457262     Source Type: Journal    
DOI: 10.4103/1008-682X.122354     Document Type: Article

References (23)

1. De La Vieja A, Dohan O, Levy O, Carrasco N. Molecular analysis of the sodium/iodide symporter: impact on thyroid and extrathyroid pathophysiology. Physiol Rev 2000; 80: 1083-105.
2. Spitzweg C, Heufelder AE, Morris JC. Thyroid iodine transport. Thyroid 2000; 10: 321-30.
3. Dai G, Levy O, Carrasco N. Cloning and characterization of the thyroid iodide transporter. Nature 1996; 379: 458-60.
4. Smanik PA, Liu Q, Furminger TL, Ryu K, Xing S, et al. Cloning of the human sodium iodide symporter. Biochem Biophys Res Commun 1996; 226: 339-45.
5. Smanik PA, Ryu KY, Theil KS, Mazzaferri EL, Jhiang SM. Expression, exon-intron organization, and chromosome mapping of the human sodium iodide symporter. Endocrinol 1997; 138: 3555-8.
6. Mazzaferri EL. Carcinoma of follicular epithelium: radioiodine and other treatments and outcomes. In: Braverman LE, Utiger RD, editors. The Thyroid: A Fundamental and Clinical Text. Lippincott-Raven: Philadelphia; 1996. p. 922-45.
7. Cho JY, Xing S, Liu X, Buckwalter TL, Hwa L, et al. Expression and activity of human Na+/I-symporter in human glioma cells by adenovirus-mediated gene delivery. Gene Therapy 2000; 7: 740-9.
8. Shimura H, Haraguchi K, Miyazaki A, Endo T, Onaya T. Iodide uptake and experimental 131I therapyin transplanted undifferentiated thyroid cancer cells expressingthe Na+/I-symporter gene. Endocrinol 1997; 138: 4493-6.
9. Mandell RB, Mandell LZ, Link CJ Jr. Radioisotope concentrator gene therapy using the sodium/iodide symporter gene. Cancer Res 1999; 59: 661-8.
10. Boland A, Ricard M, Opolon P. Adenovirus-mediated transfer of the thyroid sodium/iodide symporter gene into tumors for a targeted radiotherapy. Cancer Res 2000; 60: 3484-92.
11. Xie BX, Zhang H, Yu L, Wang J, Pang B, et al. The radiation response of androgen-refractory prostate cancer cell line C4-2 derived from androgen-sensitive cell line LNCaP. Asian J Androl 2010; 12: 405-14.
12. Spitzweg C, Zhang S, Bergert ER, Castro MR, McIver B, et al. Prostate-specific antigen (PSA) promoter driven androgen-inducible expression of sodium iodide symporter in prostate cancer cell lines. Cancer Res 1999; 59: 2136-41.
13. Igawa T, Lin FF, Lee MS, Karan D, Batra SK, et al. Establishment and characterization of androgen-independent human prostate cancer LNCaP cell model. Prostate 2002; 50: 222-35.
14. Spitzweg C, O'Connor MK, Bergert ER, Tindall DJ, Young CY, et al. Treatment of prostate cancer by radioiodine therapy after tissue-specific expression of the sodium iodide symporter. Cancer Res 2000; 60: 6526-30.
15. Weiss SJ, Philp NJ, Grollman EF. Iodine transport in a continous line of cultured cells from rat thyroid. Endocrinol 1984; 114: 1090-8.
16. Trujillo MA, Oneal MJ, McDonough S, Qin R, Morris JC. A probasin promoter, conditionally replicating adenovirus that expresses the sodium iodide symporter (NIS) for radiovirotherapy of prostate cancer. Gene Ther 2010; 17: 1325-32.
17. Huang R, Zhao Z, Ma X, Li S, Gong R, et al. Targeting of tumor radioiodine therapy by expression of the sodium iodide symporter under control of the survivin promoter. Cancer Gene Ther 2011; 18: 144-52.
18. Wright GL Jr, Grob BM, Haley C, Grossman K, Newhall K, et al. Upregulation of prostate-specific membrane antigen after androgen-deprivation therapy. Urology 1996; 48: 326-34.
19. Israeli RS, Powell CT, Corr JG, Fair WR, Heston WD. Expression of the prostate-specific membrane antigen. Cancer Res 1994; 54: 1807-11.
20. Silver DA, Pellicer I, Fair WR, Heston WD, Cordon-Cardo C. Prostate-specific membrane antigen expression in normal and malignant human tissues. Clin Cancer Res 1997; 3: 81-5.
21. O'Keefe DS, Su SL, Bacich DJ, Horiguchi Y, Luo Y, et al. Mapping, genomic organization and promoter analysis of the human prostate specific membrane antigen gene. Biochim Biophys Acta 1998; 1443: 113-27.
22. 131I. PLoS One 2012; 7: e32871.
23. Barton KN, Stricker H, Elshaikh MA, Pegg J, Cheng J, et al. Feasibility of adenovirus-mediated hNIS gene transfer and 131I radioiodine therapy as a definitive treatment for localized prostate cancer. Mol Ther 2011; 19: 1353-9.